Zhang Peng, Leng Yifu, Liu Yuanxin, Liu Jiayi, Li Chaoran, Qin Jie
Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Department of Reproduction Medicine Center, The Affiliated Zhongshan Hospital, Dalian University, Dalian, China.
Front Endocrinol (Lausanne). 2025 May 19;16:1487650. doi: 10.3389/fendo.2025.1487650. eCollection 2025.
Male infertility, a complex multifactorial condition, is frequently caused by asthenozoospermia (AZS). Although osteopontin (OPN) has been implicated in mammalian reproduction, its specific effects on sperm motility and fertility are not well understood. This study investigates the relationships between seminal plasma OPN levels and sperm parameters in cases of male infertility.
A total of 158 semen samples were analyzed, comprising 78 from infertile men with AZS and 80 from healthy fertile controls. OPN concentrations in seminal plasma were measured using the ELISA method. Additionally, we assessed the effect of OPN on sperm motility parameters in AZS patients and controls.
Significantly lower OPN concentrations were observed in the seminal plasma of infertile men with AZS compared to healthy controls (<0.0001). OPN levels discriminated between the groups, with an area under the curve of 0.793. Additionally, OPN treatment significantly improved sperm motility in the AZS group, enhancing progressive and total motility, as well as kinematic parameters in a concentration-dependent manner.
This study established a link between OPN level and sperm motility in infertile individuals with AZS, suggesting the potential of OPN as a biomarker for AZS and as a supplement for assisted reproductive techniques.
男性不育是一种复杂的多因素疾病,常由弱精子症(AZS)引起。尽管骨桥蛋白(OPN)与哺乳动物生殖有关,但其对精子活力和生育能力的具体影响尚不清楚。本研究调查男性不育患者精浆OPN水平与精子参数之间的关系。
共分析了158份精液样本,其中78份来自患有AZS的不育男性,80份来自健康的可育对照者。采用ELISA法测定精浆中OPN浓度。此外,我们评估了OPN对AZS患者和对照者精子活力参数的影响。
与健康对照者相比,患有AZS的不育男性精浆中OPN浓度显著降低(<0.0001)。OPN水平可区分两组,曲线下面积为0.793。此外,OPN治疗显著改善了AZS组的精子活力,以浓度依赖的方式提高了前向运动和总运动能力以及运动学参数。
本研究建立了OPN水平与患有AZS的不育个体精子活力之间的联系,表明OPN作为AZS生物标志物和辅助生殖技术补充剂的潜力。